Trials / Completed
CompletedNCT04767529
A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 128 (actual)
- Sponsor
- Akero Therapeutics, Inc · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in non-cirrhotic subjects with biopsy-proven F2 - F3 NASH.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Efruxifermin | subcutaneous injection |
| DRUG | Placebo | subcutaneous injection |
Timeline
- Start date
- 2021-02-16
- Primary completion
- 2024-05-02
- Completion
- 2024-05-02
- First posted
- 2021-02-23
- Last updated
- 2025-06-18
- Results posted
- 2025-05-08
Locations
55 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04767529. Inclusion in this directory is not an endorsement.